Abstract:Mitochondria are an essential intracellular organelle for medication targeting and delivery since they seem to create energy and conduct many other cellular tasks, and mitochondrial dysfunctions and malfunctions lead to many illnesses. Many initiatives have been taken to detect, diagnose, and image mitochondrial abnormalities, and to transport and accumulate medicines precisely to mitochondria, all because of special mitochondrial aspects of the pathophysiology of cancer. In addition to the negative membrane potential and paradoxical mitochondrial dynamics, they include high temperatures, high levels of reactive oxygen species, high levels of glutathione, and high temperatures. Neurodegenerative diseases represent a broad spectrum of debilitating illnesses. They are linked to the loss of certain groups of neurons based on an individual's physiology or anatomy. The mitochondria in a cell are generally accepted as the authority with respect to ATP production. Disruption of this system is linked to several cellular physiological issues. The development of neurodegenerative disorders has been linked to mitochondrial malfunction, according to pathophysiological studies. There seems to be substantial evidence connecting mitochondrial dysfunction and oxidative stress to the development of neurodegenerative disorders. It has been extensively observed that mitochondrial malfunction triggers autophagy, which plays a role in neurodegenerative disorders. In addition, excitotoxicity and mitochondrial dysfunction have been linked to the development of neurodegenerative disorders. The pathophysiology of neurodegenerative illnesses has been linked to increased apoptosis and necrosis, as well as mitochondrial malfunction. A variety of synthetic and natural treatments have shown efficacy in treating neurodegenerative illnesses caused by mitochondrial failure. Neurodegenerative illnesses can be effectively treated with existing drugs that target mitochondria, although their precise formulations are poorly understood. Therefore, there is an immediate need to focus on creating drug delivery methods specifically targeted at mitochondria in the treatment and diagnosis of neurodegenerative disorders.

Targeted to Neuronal Organelles for CNS Drug Development

Mitochondria and Other Organelles in Neural Development and Their Potential as Therapeutic Targets in Neurodegenerative Diseases

Subcellular Visualization: Organelle-Specific Targeted Drug Delivery and Discovery

Mitochondrion-based organellar therapies for central nervous system diseases

Mitochondria targeting drugs for neurodegenerative diseases—Design, mechanism and application

Organelle Targeted Drug Delivery: Key Challenges, Recent Advancements and Therapeutic Implications

Targeting mitophagy for neurological disorders treatment: advances in drugs and non-drug approaches

Organelle-level precision with next-generation targeting technologies

Targeting Emerging Pathogenic Mechanisms by Natural Molecules as Potential Therapeutics for Neurodegenerative Diseases

The Dynamics Of The Mitochondrial Organelle As A Potential Therapeutic Target

Mitochondrial dynamics in neurological diseases: a narrative review

Mitochondrial Dynamics: A Key Role in Neurodegeneration and a Potential Target for Neurodegenerative Disease

Enhancing CNS mitophagy: drug development and disease-relevant models

Targeting selective autophagy in CNS disorders by small-molecule compounds

Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System

Cell-Membrane-Coated Nanoparticles for Targeted Drug Delivery to the Brain for the Treatment of Neurological Diseases

ER-organelle contacts: A signaling hub for neurological diseases

Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases

Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles

Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders

Advances in novel anti-neurodegenerative diseases drugs targeting mitochondria